BioCardia
BioCardia is dedicated to developing cellular and cell-derived therapeutics for the treatment of unmet cardiovascular and pulmonary diseases. Their lead program, CardiAMP®, is an autologous mononuclear cell therapy aimed at treating ischemic heart failure with reduced ejection fraction. The company is actively involved in clinical trials and scientific research to advance targeted cellular precision medicines for cardiovascular and pulmonary conditions.
Industries
Nr. of Employees
small (1-50)
Patents
Method of accessing the left atrium with a multi-directional steerable catheter
US-12036371-B2
View DetailsMethods of measuring potential for therapeutic potency and defining dosages for autologous cell therapies
US-11828757-B2
View DetailsBone marrow derived neurokinin-1 receptor positive (NK1R+) mesenchymal stem cells for therapeutic applications
US-11642377-B2
View Details
Method of accessing the left atrium with a multi-directional steerable catheter
US-12036371-B2
View DetailsMethods of measuring potential for therapeutic potency and defining dosages for autologous cell therapies
US-11828757-B2
View DetailsBone marrow derived neurokinin-1 receptor positive (NK1R+) mesenchymal stem cells for therapeutic applications
US-11642377-B2
View DetailsProducts
Autologous bone marrow mononuclear cell therapy for ischemic heart failure
A clinical-stage autologous cell therapy program developed for patients with ischemic heart failure, evaluated in randomized and pivotal clinical trials.
Allogeneic cell therapy program for heart failure and pulmonary indications
An allogeneic cell therapy development program targeting heart failure and acute respiratory distress indications with early-stage clinical evaluation.
Transendocardial biotherapeutic delivery system
A catheter-based transendocardial delivery system used to administer cells intramyocardially and evaluated across clinical practice and studies.
Autologous bone marrow mononuclear cell therapy for ischemic heart failure
A clinical-stage autologous cell therapy program developed for patients with ischemic heart failure, evaluated in randomized and pivotal clinical trials.
Allogeneic cell therapy program for heart failure and pulmonary indications
An allogeneic cell therapy development program targeting heart failure and acute respiratory distress indications with early-stage clinical evaluation.
Transendocardial biotherapeutic delivery system
A catheter-based transendocardial delivery system used to administer cells intramyocardially and evaluated across clinical practice and studies.
Services
Sponsorship and operational execution of multicenter clinical studies evaluating cell-based therapeutics for heart failure and related conditions.
Preclinical evaluation of catheter-based delivery performance in large-animal models to support device and therapy optimization.
Sponsorship and operational execution of multicenter clinical studies evaluating cell-based therapeutics for heart failure and related conditions.
Preclinical evaluation of catheter-based delivery performance in large-animal models to support device and therapy optimization.
Expertise Areas
- Cell therapy development for cardiovascular disease
- Autologous and allogeneic cell therapy programs
- Transendocardial catheter-based delivery
- Point-of-care cell processing and potency assessment
Key Technologies
- Catheter-based transendocardial delivery
- Autologous bone marrow mononuclear cell therapy
- Allogeneic mesenchymal stromal cell therapy
- Ex vivo cell expansion and CD34+ cell preparation